1.47
0.02 (1.51%)
| Previous Close | 1.45 |
| Open | 1.50 |
| Volume | 195,637 |
| Avg. Volume (3M) | 309,042 |
| Market Cap | 67,308,512 |
| Price / Sales | 10.21 |
| Price / Book | 2.12 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -6,511.20% |
| Diluted EPS (TTM) | -1.64 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 64.59% |
| Current Ratio (MRQ) | 8.10 |
| Operating Cash Flow (TTM) | -59.84 M |
| Levered Free Cash Flow (TTM) | -36.80 M |
| Return on Assets (TTM) | -32.66% |
| Return on Equity (TTM) | -82.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Werewolf Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.00 |
|
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.07% |
| % Held by Institutions | 62.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Asset Management Llc | 30 Jun 2025 | 4,309,860 |
| Dc Funds, Lp | 30 Jun 2025 | 589,102 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (B of A Securities, 443.52%) | Buy |
| Median | 5.50 (273.67%) | |
| Low | 3.00 (JMP Securities, 103.82%) | Buy |
| Average | 5.50 (273.67%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 25 Aug 2025 | 8.00 (443.52%) | Buy | 1.37 |
| JMP Securities | 21 Aug 2025 | 3.00 (103.82%) | Buy | 1.28 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| EVNIN LUKE | - | 1.62 | -177,145 | -285,072 |
| GADICKE ANSBERT | - | 1.62 | -276,017 | -444,183 |
| MPM BIOVENTURES 2014, L.P. | - | 1.62 | -276,017 | -444,183 |
| Aggregate Net Quantity | -729,179 | |||
| Aggregate Net Value ($) | -1,173,438 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1.62 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GADICKE ANSBERT | 29 Oct 2025 | Automatic sell (-) | 134,240 | 1.56 | 209,414 | |
| MPM BIOVENTURES 2014, L.P. | 29 Oct 2025 | Automatic sell (-) | 134,240 | 1.56 | 209,414 | |
| EVNIN LUKE | Director | 29 Oct 2025 | Automatic sell (-) | 86,154 | 1.56 | 134,400 |
| GADICKE ANSBERT | 28 Oct 2025 | Automatic sell (-) | 69,068 | 1.62 | 111,890 | |
| MPM BIOVENTURES 2014, L.P. | 28 Oct 2025 | Automatic sell (-) | 69,068 | 1.62 | 111,890 | |
| EVNIN LUKE | Director | 28 Oct 2025 | Automatic sell (-) | 44,327 | 1.62 | 71,810 |
| GADICKE ANSBERT | 27 Oct 2025 | Automatic sell (-) | 72,709 | 1.69 | 122,878 | |
| MPM BIOVENTURES 2014, L.P. | 27 Oct 2025 | Automatic sell (-) | 72,709 | 1.69 | 122,878 | |
| EVNIN LUKE | Director | 27 Oct 2025 | Automatic sell (-) | 46,664 | 1.69 | 78,862 |
| Date | Type | Details |
|---|---|---|
| 04 Nov 2025 | Announcement | Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 08 Oct 2025 | Announcement | Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer |
| 03 Oct 2025 | Announcement | Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting |
| 02 Sep 2025 | Announcement | Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference |
| 14 Aug 2025 | Announcement | Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |